acquir
immunodefici
syndrom
aid
first
describ
unit
state
unexplain
appear
kaposi
sarcoma
pneumocysti
carinii
pneumonia
opportunist
infect
previous
healthi
homosexu
male
affect
individu
becam
suscept
opportunist
infect
specif
immun
defici
result
deplet
lymphocyt
intens
investig
reveal
etiolog
agent
aid
lymphotrop
retroviru
human
immunodefici
viru
hiv
today
three
class
drug
avail
treat
patient
infect
hiv
nucleosid
revers
transcriptas
inhibitor
nrti
nonnucleosid
revers
transcriptas
inhibitor
nnrti
proteas
inhibitor
pi
current
accept
standard
care
hiv
infect
involv
use
three
drug
combin
regimen
use
combin
therapi
profoundli
reduc
morbid
mortal
associ
hiv
infect
howev
approv
antihiv
drug
combin
drug
signific
limit
includ
toxic
select
drugresist
variant
pharmacokinet
interact
agent
poor
adher
due
complex
dose
regimen
limit
necessit
continu
search
antihiv
agent
improv
clinic
profil
hepat
b
viru
hbv
also
constitut
major
worldwid
health
threat
addit
morbid
associ
acut
clinic
infect
chronic
liver
diseas
cirrhosi
hepat
delta
viru
infect
primari
hepatocellular
carcinoma
recogn
sequela
reservoir
hbv
includ
estim
worldwid
popul
million
carrier
approxim
chronic
carrier
die
primari
hepatocellular
carcinoma
cirrhosi
liver
present
two
approv
therapi
treatment
hbv
infect
ainterferon
lamivudin
limit
efficaci
ainterferon
emerg
lamivudineresist
hbv
variant
made
clear
addit
therapi
need
treatment
acut
chronic
hbv
infect
new
therapi
includ
combin
regimen
analog
use
treat
hiv
infect
f
figur
structur
emtricitabin
ftc
oxathiolan
ring
analog
ring
l
configur
correspond
posit
contrast
natur
occur
nucleosid
configur
posit
clinic
studi
demonstr
drug
effect
suppress
hiv
hbv
infect
patient
report
present
overview
prechnic
clinic
studi
conduct
date
emtricitabin
possibl
critiqu
differ
emtricitabin
nucleosid
analog
current
approv
treatment
hiv
hbv
diseas
particular
attent
paid
compar
antivir
activ
emtricitabin
lamivudin
differenti
activ
two
compound
base
introduct
fluorin
posit
emtricitabin
antivir
activ
emtricitabin
shown
specif
hbv
activ
observ
concentr
im
hcmv
vzv
coronaviru
yellow
fever
viru
respiratori
syncyti
viru
rotaviru
influenza
viru
rhino
vim
abil
emtricitabin
inhibit
replic
cell
cultur
studi
extens
use
variou
human
tlymphoid
cell
line
cem
pmbc
infect
laboratoryadapt
strain
illg
lai
lav
zy
result
summar
tabl
comparison
vitro
potenc
emtricitabin
nucleosid
analogu
current
use
treat
hiv
difficult
owe
wide
varieti
cell
type
viru
strain
assay
condit
use
numer
investig
determin
ecq
valu
compound
howev
ecq
data
deriv
pbmc
infect
lai
lav
illg
strain
use
basi
comparison
emtricitabin
nucleosid
analogu
current
approv
human
use
divid
three
potenc
group
potent
group
includ
emtricitabin
azt
ecg
valu
rang
jm
lom
respect
second
potenc
group
includ
ddc
ecq
valu
rang
jom
jm
respect
least
potent
group
includ
ddl
abacavir
ec
valu
rang
jom
jm
respect
tabl
inhibitori
op
person
commun
k
borrotoesoda
triangl
pharmaceut
sever
investig
compar
antihiv
activ
emtricitabin
lamivudin
assay
therebi
elimin
ambigu
introduc
interassay
comparison
result
summar
tabl
although
differ
laboratori
strain
viru
differ
cell
type
differ
assay
method
use
investig
studi
emtricitabin
consist
show
greater
activ
lamivudin
activ
advantag
rang
threeto
sensit
clinic
isol
inhibit
antihiv
drug
assess
vitro
gain
insight
variat
activ
might
encount
clinic
set
result
one
studi
conduct
emtricitabin
human
pbmc
present
tabl
schinazi
et
al
test
two
low
passag
clinic
isol
phytohemagglutininstimul
pbmc
isol
uninfect
donor
ecq
valu
similar
calcul
use
laboratori
strain
viru
pbmc
sensit
emtricitabin
report
two
addit
wild
type
clinic
isol
wtpreazt
obtain
richman
veteran
affair
medic
center
san
diego
ca
obtain
phase
emivirin
trial
triangl
pharmaceut
inc
similar
determin
schinazi
et
al
singl
experi
direct
comparison
made
activ
emtricitabin
lamivudin
emtricitabin
demonstr
fivefold
potenc
advantag
seen
use
laboratori
strain
viru
potenc
emtricitabin
also
determin
use
cocultur
assay
compar
directli
potenc
lamivudin
zalcitabin
didanosin
zidovudin
nonnucleosid
rt
inhibitor
tibo
studi
pbmc
hivinfect
patient
cocultur
pbmc
isol
uninfect
donor
natur
infect
pbmc
serv
sourc
diversifi
popul
viru
select
vitro
propag
end
cocultur
period
degre
viral
replic
measur
elisa
result
studi
express
mean
ec
ec
ec
valu
given
tabl
potenc
rank
base
ecq
valu
show
emtricitabin
potent
compound
follow
zalcitabin
lamivudin
zidovudin
tibo
didanosin
low
potenc
rank
zidovudin
compar
observ
laboratori
strain
may
result
inclus
pmbc
aztexperienc
patent
cocultur
determin
antivir
activ
emtricitabin
vari
differ
subtyp
activ
evalu
group
group
cell
pbmc
tabl
show
result
ecq
valu
also
obtain
lamivudin
zidovudin
didanosin
emtricitabin
activ
lamivudin
didanosin
activ
compar
zidovudin
vitro
antihbv
activ
emtricitabin
studi
extens
use
stabli
hbvtransfect
cell
line
tabl
comparison
ec
valu
nucleosid
analogu
current
develop
antihbv
agent
present
along
emtricitabin
lamivudin
tabl
contrast
hiv
ecq
valu
emtricitabin
lamivudin
similar
hbv
condreay
et
al
examin
effect
emtricitabin
hbv
replic
primari
human
hepatocyt
although
ecq
valu
calcul
emtricitabin
lom
complet
inhibit
product
intracellular
hbv
dna
even
ad
hour
infect
ec
valu
calcul
inhibit
extracellular
vim
product
ilm
valu
compar
determin
cell
tabl
transport
studi
conduct
confluent
cultur
cell
determin
rout
cellular
uptak
emtricitabin
assay
perform
room
temperatur
use
modifi
rapid
cold
buffer
stop
method
influx
emtricitabin
cell
depend
concentr
emtricitabin
presenc
na
gradient
partial
inhibit
compet
nucleosid
nucleosid
transport
inhibitor
tabl
neglig
impact
protein
modif
agent
nethylmaleimid
acid
acid
emtricitabin
uptak
suggest
compon
emtricitabin
entri
cell
transport
mediat
possibl
result
nonfacilit
diffus
tabl
inhibit
emtricitabin
influx
cell
nucleosid
transport
inhibitor
compet
nucleosid
adenin
emtricitabin
effici
phosphoryl
cell
correspond
time
cours
show
nucleotid
emtricitabin
form
rapidli
reach
steadyst
intracellular
concentr
three
six
hour
concentr
emtricitabin
somewhat
higher
concentr
deriv
shown
figur
intracellular
concentr
phosphoryl
form
measur
function
extracellular
concentr
concentr
rang
jlim
concentr
deriv
emtricitabin
increas
dosedepend
manner
indic
anabol
pathway
satur
concentr
test
figur
intracellular
halflif
approxim
hour
determin
emtricitabin
cell
halflif
extrem
short
compar
estim
hour
halflif
seen
pbmc
taken
healthi
human
volunt
dose
oral
mg
emtricitabin
qd
studi
determin
enzym
respons
phosphoryl
emtricitabin
kinas
identifi
enzym
catalyz
phosphoryl
emtricitabin
correspond
use
calf
thymu
kinas
rel
experi
cell
incub
emtricitabin
hour
rate
phosphoryl
measur
observ
shewach
et
al
demonstr
emtricitabin
good
substrat
human
deoxycytidin
kinas
appar
k
valu
appar
rel
v
nmolmlhr
determin
utp
phosphat
donor
atp
phosphat
donor
appar
k
valu
im
appar
rel
v
nmolmlhr
obtain
phosphoryl
catalyz
monophosph
kinas
effici
enzym
purifi
calf
thymu
phosphoryl
emtricitabin
approxim
observ
use
natur
substrat
emtricitabin
also
phosphoryl
nucleosid
monophosph
kinas
purifi
beef
liver
howev
phosphoryl
catalyz
enzym
rel
ineffici
format
emtricitabin
propos
catalyz
nucleosid
diphosph
kinas
ndp
cytosol
enzym
broad
specif
nucleosid
howev
cheng
et
al
recent
suggest
lnucleotid
util
substrat
ndp
kinas
select
phosphoryl
kinas
inhibit
revers
transcriptas
emtricitabin
human
immunodefici
vim
encod
revers
transcriptas
hivrt
synthes
doublestrand
dna
copi
genom
rna
emtricitabin
serv
altern
substrat
inhibitor
hiyrt
incorpor
grow
chain
viral
dna
incorpor
result
termin
nascent
chain
dna
synthesi
due
lack
hydroxi
group
sugar
moieti
emtricitabin
turn
result
inhibit
viral
replic
steadi
state
kinet
experi
compar
emtricitabin
natur
substrat
dctp
show
two
substrat
similar
k
valu
hivrt
nm
emtricitabin
nm
dctp
k
valu
emtricitabin
inhibit
hivrtcatalyz
rnadepend
dna
synthesi
dnadepend
dna
synthesi
calcul
jm
im
respect
comparison
k
valu
lamivudin
inhibit
hivrtcatalyz
rnadepend
dnadepend
dna
synthesi
nm
respect
although
steadi
state
kinet
analysi
repres
use
begin
insuffici
establish
detail
kinet
mechanist
pictur
enzymecatalyz
reaction
presteadyst
kinet
analysi
provid
detail
pictur
event
occur
enzym
activ
site
includ
bind
nucleotid
substrat
enzymedna
complex
form
initi
ternari
complex
kj
maximum
rate
incorpor
singl
nucleotid
k
overal
effici
incorpor
defin
quotient
k
k
use
rapid
quench
techniqu
carri
presteadyst
analysi
feng
et
al
compar
presteadyst
kinet
singl
nucleotid
incorpor
dctp
lamivudin
emtricitabin
opposit
templat
guanosin
rnadepend
dna
synthesi
rt
result
shown
tabl
overal
incorpor
rate
oxathiolan
nucleosid
analog
significantli
slower
observ
natur
substrat
dctp
evidenc
valu
k
j
k
j
valu
dctp
rang
time
greater
correspond
k
j
valu
oxathiolan
nucleosid
analogu
howev
k
valu
reveal
oxathiolan
substrat
bind
much
tighter
enzymedna
complex
natur
substrat
k
valu
analogu
approxim
sixto
lower
natur
substrat
k
k
j
valu
reveal
emtricitabin
better
overal
substrat
enzym
lamivudin
result
k
k
advantag
increas
effici
emtricitabin
rel
lamivudin
emtricitabin
incorpor
almost
order
magnitud
effici
lamivudin
rnadepend
dna
synthesi
effici
advantag
account
part
higher
activ
seen
emtricitabin
compar
lamivudin
cell
cultur
tabl
inhibit
hbv
dna
polymeras
emtricitabin
replic
cycl
hepadnaviru
includ
revers
transcript
rna
templat
process
carri
polymeras
share
signific
sequenc
homolog
rt
retrovirus
includ
hiv
sinc
attempt
date
purifi
human
hbv
dna
polymeras
unsuccess
examin
effect
emtricitabin
hbv
dna
polymeras
carri
use
endogen
polymeras
assay
assay
intact
viru
particl
treat
nonion
deterg
partial
disrupt
viru
particl
allow
nucleotid
substrat
enter
viru
particl
dna
synthesi
occur
hbv
particl
purifi
cultur
supemat
treat
deterg
shown
incorpor
emtricitabin
inhibit
product
format
dosedepend
fashion
competit
studi
perform
determin
whether
emtricitabin
compet
dctp
bind
enzym
substrat
well
experi
abil
increas
concentr
dctp
dttp
dgtp
block
inhibit
dna
synthesi
emtricitabin
examin
increas
concentr
dttp
dgtp
effect
inhibit
emtricitabin
tenfold
excess
dctp
complet
block
abil
emtricitabin
inhibit
dna
synthesi
davi
et
al
use
endogen
polymeras
assay
demonstr
hbv
dna
polymeras
could
incorpor
ap
emtricitabin
minu
strand
dna
studi
ap
emtricitabin
incub
hbv
viral
particl
x
isol
cell
cultur
unlabel
datp
dgtp
dctp
radiolabel
dna
product
detect
autoradiographi
label
kb
dna
detect
indic
radiolabel
emtricitabin
incorpor
viral
dna
endogen
polymeras
assay
use
hbv
vim
particl
isol
cell
cultur
treat
emtricitabin
show
either
reduc
polymeras
activ
depend
concentr
emtricitabin
use
even
though
detect
hbv
minu
strand
dna
furthermor
particl
produc
emtricitabin
cell
contain
detect
hbv
plu
strand
dna
consist
incorpor
chain
termin
activ
emtricitabin
taken
togeth
result
demonstr
emtricitabin
serv
altern
substrat
inhibitor
hbv
dna
polymeras
select
enzym
level
effect
human
dna
polymeras
p
e
gain
insight
origin
select
antivir
activ
exhibit
emtricitabin
inhibit
purifi
human
hela
cell
dna
polymeras
p
emtricitabin
examin
steadyst
condit
compar
inhibit
hiv
rt
activ
calf
thymu
dna
use
templat
analysi
enzym
condit
emtricitabin
weak
inhibitor
human
dna
polymeras
compar
hiv
rt
appar
kj
valu
lim
polymeras
jom
polymeras
p
jlim
polymeras
lim
polymeras
e
compar
kj
valu
nm
rt
longterm
treatment
nucleosid
analogu
associ
variou
form
toxic
inhibit
human
dna
polymeras
pol
one
propos
mechan
nucleosid
analogderiv
toxic
form
mani
nucleosid
analog
shown
serv
substrat
pol
result
inhibit
mitochondri
dna
synthesi
therefor
potenti
emtricitabin
lamivudin
serv
substrat
pol
investig
j
feng
person
commun
triangl
pharmaceut
dctp
emtricitabin
lamivudin
order
incorpor
effici
dctp
lamivudin
emtricitabin
low
rate
incorpor
poor
bind
affin
emtricitabin
make
least
favor
substrat
pol
excis
dna
pol
yassoci
exonucleas
activ
rescu
mitochondri
dna
synthesi
chain
termin
effect
nucleotid
analog
j
feng
person
commun
triangl
pharmaceut
unmodifi
primer
termin
natur
cytidin
nucleotid
dcmp
shown
best
substrat
pol
yassoci
exonucleas
follow
emtricitabin
lamivudin
littl
differ
observ
abil
pol
yassoci
exonucleas
excis
emtricitabin
lamivudin
termin
primer
overal
studi
dna
pol
demonstr
emtricitabin
lower
inhibitori
effect
mitochondri
enzym
lamivudin
therefor
may
less
like
caus
mitochondri
toxic
long
term
antihiv
activ
emtricitabin
test
scid
sever
combin
immunodefici
mice
mice
reconstitut
human
pbmc
two
week
infect
hlvljg
viru
drug
therapi
initi
one
day
infect
test
compound
administ
intraperiton
twice
daili
mgkg
viral
inhibit
measur
quantit
cocultur
infect
quantit
rna
viral
load
measur
periton
wash
cell
lymph
node
spleen
cell
plasma
concentr
use
studi
emtricitabin
complet
inhibit
viral
infect
black
furman
person
commun
triangl
pharmaceut
evalu
antihiv
activ
oral
administ
emtricitabin
lamivudin
side
side
hupbmcscid
mous
model
group
femal
scid
mice
reconstitut
intraperiton
ip
inject
x
human
pbmc
two
week
later
mice
infect
ip
tissu
cultur
infecti
dose
tcid
hivlqjg
infect
mice
weigh
random
treatment
control
group
mice
treatment
group
receiv
singl
ipload
dose
drug
drug
administ
drink
water
contain
mgml
emtricitabin
water
bottl
weigh
begin
end
treatment
water
consumpt
could
calcul
seven
day
infect
mice
anesthest
weigh
euthan
exsanguin
viral
load
plasma
measur
use
realtim
revers
transcriptasepolymeras
chain
reaction
rtpcr
emtricitabin
lamivudin
well
toler
seven
day
studi
evid
toxic
averag
anim
weight
daili
water
consumpt
three
group
similar
thu
averag
daili
dose
two
drug
similar
mgkg
control
group
geometr
mean
viral
load
x
copiesml
emtricitabin
reduc
plasma
viral
load
limit
detect
treat
mice
lamivudin
reduc
plasma
viral
load
limit
detect
treat
mice
reduct
viral
load
treatment
group
statist
signific
p
compar
control
differ
significantli
vivo
antihepat
activ
emtricitabin
first
test
chimer
mous
model
nih
bgnuxid
mice
subcutan
inject
suspens
cell
subcutan
inject
cell
result
develop
tumor
cell
produc
hbv
hbv
could
detect
serum
sampl
tumorbear
mice
use
immunoaffin
system
link
quantit
pcr
begin
one
week
postinject
mice
dose
oral
mgkgday
emtricitabin
comparison
tumor
progress
human
afetoprotein
level
control
versu
drugdos
mice
indic
emtricitabin
antitumor
activ
howev
emtricitabin
mgkgday
dose
significantli
reduc
circulatori
level
hbv
dna
examin
tumor
extract
two
dose
group
reveal
mark
reduct
intracellular
level
replic
dna
hbv
intermedi
includ
doublestrand
linear
dna
antihbv
activ
also
report
emtricitabin
hbv
transgen
scid
mice
group
five
mice
treat
emtricitabin
mgkgday
ip
six
day
observ
addit
six
day
posttreat
day
three
treatment
two
mice
undetect
hbsag
addit
two
mice
clear
hbsag
day
five
remain
mous
clear
hbsag
day
eight
hbv
dna
level
blood
determin
semiquantit
pcr
day
day
three
treatment
pcr
signal
drop
tenfold
mice
day
eight
none
mice
detect
hbv
dna
level
pcr
contrast
lamivudin
sign
rebound
level
hbv
dna
cours
treatment
dhbv
duck
hepat
b
viru
use
surrog
viru
test
vivo
activ
compound
studi
potenti
antihbv
drug
although
dhbv
differ
genu
hepadnavirida
hbv
avihepadnaviru
rather
orthohepadnaviru
signific
enough
structur
biolog
related
hbv
support
use
vivo
model
emtricitabin
first
test
dhbv
pilot
studi
congenit
infect
duckl
treat
oral
dose
mgkg
bid
studi
establish
emtricitabin
inhibit
viral
replic
well
toler
longerterm
studi
util
mgkg
bid
dose
regimen
four
adult
duck
dose
week
determin
efficaci
emtricitabin
primari
goal
studi
howev
compound
describ
effect
reduc
viremia
tenfold
four
day
treatment
nearli
undetect
level
within
week
liver
biopsi
conduct
two
six
week
treatment
reveal
signific
dechn
replic
form
viral
dna
consist
abil
emtricitabin
act
altern
substrat
inhibitor
dhbv
polymeras
howev
level
cccdna
circular
coval
close
dna
declin
much
slowli
drop
two
six
week
therapi
respect
woodchuck
hepat
viru
whv
natur
host
eastern
woodchuck
marmota
monax
accept
frequent
use
model
hepatitisinduc
diseas
princip
three
reason
whv
similar
hbv
hepadnavirida
avail
anim
model
system
hbv
whv
member
genu
orthohepadnaviru
share
approxim
nucleotid
sequenc
homolog
rang
hepat
injuri
produc
chronic
infect
woodchuck
close
resembl
seen
hbvinfect
human
rel
vivo
effect
antivir
agent
compar
whv
hbv
four
antivir
agent
previous
studi
antihbv
activ
clinic
trial
studi
whv
result
compar
back
clinic
trial
result
comparison
show
parallel
activ
observ
clinic
reinforc
util
chronic
whv
infect
woodchuck
vivo
evalu
agent
develop
chronic
hbv
infect
emtricitabin
demonstr
profound
antihepat
viru
activ
woodchuck
model
oral
dose
studi
five
group
chronic
infect
woodchuck
given
emtricitabin
qd
one
five
dose
mgkg
four
week
dose
mgkg
greater
emtricitabin
induc
statist
signific
reduct
serum
viremia
replic
intermedi
largest
reduct
viremia
approxim
log
replic
intermedi
approxim
seen
mgkg
dose
signific
effect
level
intrahepat
rna
serum
level
whsag
appear
antibodi
whsag
whcag
serum
observ
viremia
return
pretreat
level
within
one
two
week
follow
end
treatment
dose
rapid
rebound
consist
lack
signific
impact
level
whv
cccdna
result
similar
obtain
group
separ
oral
qd
dose
studi
chronic
infect
woodchuck
lamivudin
decreas
serum
viremia
replic
intermedi
liver
tissu
produc
lamivudin
similar
observ
emtricitabin
compar
exposur
drug
addit
rate
degre
viral
rebound
observ
upon
cessat
therapi
virtual
ident
compound
cuuen
et
al
studi
effect
emtricitabin
whv
natur
infect
wildcaught
woodchuck
anim
dose
ip
either
mgkg
bid
four
week
administr
mgkg
dose
suppress
whv
dna
level
sixto
averag
six
anim
group
whv
dna
polymeras
serum
reduc
similar
fashion
serum
dna
polymeras
activ
measur
incorpor
p
dctp
whv
dna
profound
effect
seen
mgkg
dose
serum
whv
dna
level
reduc
averag
six
anim
group
serum
dna
polymeras
activ
similarli
reduc
whv
dna
level
liver
biopsi
specimen
also
reduc
six
anim
mgkgtreatment
group
reduct
rang
pretreat
level
author
state
level
replic
intermedi
remain
close
seen
pretreat
whv
genom
shift
toward
shorter
fragment
studi
studi
korba
et
al
level
whsag
antibodi
whsag
whcag
chang
emerg
drugresist
viru
major
concern
antihiv
chemotherapi
help
defin
combin
within
drug
use
develop
resist
emtricitabin
examin
passag
viru
vitro
presenc
drug
studi
report
tisdal
et
al
strain
zidovudineresist
mutant
hivlj
contain
mutat
passag
cell
presenc
increas
concentr
emtricitabin
lamivudin
rapid
emerg
resist
occur
compound
fourth
passag
second
passag
hivlj
ecq
valu
exceed
jim
passag
six
ec
valu
excess
im
variant
highli
crossresist
lamivudin
emtricitabin
show
crossresist
zidovudin
didanosin
nevirapin
dna
sequenc
analysi
show
chang
codon
methionin
replac
valin
base
synergi
data
zidovudin
lack
crossresist
author
suggest
combin
oxathiolan
analogu
zidovudin
might
slow
emerg
resist
emtricitabin
andor
lamivudin
inde
passag
viru
presenc
increas
concentr
emtricitabin
nm
zidovudin
abl
delay
appreci
prevent
emerg
emtricitabineresist
viru
experi
perform
schinazi
et
al
potenti
resist
develop
lamivudin
emtricitabin
evalu
serial
passag
viru
human
pbmc
presenc
increas
drug
concentr
result
present
figur
show
two
week
infect
um
lamivudin
longer
abl
inhibit
viru
replic
drugresist
variant
domin
replic
viru
popul
contrast
use
ident
condit
emtricitabin
remain
highli
activ
reduc
viru
replic
emtricitabin
still
abl
inhibit
viru
replic
week
three
week
four
concentr
lamivudin
increas
lim
concentr
emtricitabin
increas
tenfold
jum
produc
level
inhibit
emtricitabin
retain
tenfold
potenc
advantag
lamivudin
four
week
passag
data
primari
human
cell
suggest
emtricitabin
may
delay
breakthrough
resist
virus
rel
lamivudin
dna
sequenc
analysi
revers
transcriptas
gene
amplifi
resist
virus
gener
passag
experi
consist
identifi
mutat
codon
methionin
chang
either
valin
isoleucin
resist
variant
crossresist
emtricitabin
lamivudin
remain
sensit
zalcitabin
didanosin
zidovudin
pea
flt
two
nonnucleosid
revers
transcriptas
inhibitor
tibo
compound
bi
heteroaryl
piperazin
deriv
biochem
studi
perform
quantifi
chang
suscept
hiv
rt
deriv
viru
resist
emtricitabin
lamivudin
zalcitabin
viru
particlederiv
rt
obtain
supernat
human
pbmc
infect
mutant
viru
mutat
enzym
less
sensit
inhibit
emtricitabin
lamivudin
wild
type
hivjrt
howev
threefold
decreas
suscept
note
zalcitabin
similar
result
report
use
highli
purifi
clone
rt
contain
mutat
studi
k
valu
emtricitabin
lamivudin
increas
respect
compar
wild
type
hiv
rt
wilson
et
al
use
steadi
state
presteadyst
kinet
analysi
examin
effect
mutat
rt
catalyt
function
kinet
studi
show
mutat
mutat
also
found
recombin
viru
prepar
use
rna
isol
plasma
three
patient
receiv
emtricitabin
monotherapi
two
week
phenotyp
analysi
cell
demonstr
three
virus
resist
emtricitabin
crossresist
lamivudin
ecq
valu
recombin
viru
emtricitabin
lamivudin
increas
greater
rel
ecq
valu
wild
type
hivlj
one
isol
contain
mutat
remain
sensit
inhibit
zidovudin
observ
keep
report
schinazi
et
al
introduct
mutat
zidovudineresist
background
result
increas
sensit
zidovudin
emtricitabin
activ
evalu
extens
panel
clinic
isol
tabl
panel
consist
seri
recombin
wild
type
clinic
isol
recombin
isol
contain
anywher
one
mutat
consist
earlier
passag
experi
high
level
resist
impart
introduct
mutat
mutat
background
moder
resist
emtricitabin
seen
highli
mutat
isol
klole
contain
two
mutat
associ
moder
resist
lamivudin
tabl
phenotyp
treatment
hevinfect
patient
lamivudin
shown
effect
suppress
viru
replic
reduc
inflammatori
activ
howev
resist
agent
document
associ
mutat
ymdd
motif
domain
c
viral
dna
polymeras
analog
chang
seen
ymdd
motif
hivrt
methionin
mutat
either
isoleucin
valin
mutat
almost
alway
observ
conjunct
addit
mutat
b
domain
sequenc
homolog
activ
site
hiv
rt
hbv
dna
polymeras
import
ymdd
motif
catalyt
activ
polymeras
role
methionin
resist
lamivudin
emtricitabin
would
anticip
hbv
contain
either
mutat
crossresist
emtricitabin
inhibit
assay
perform
use
hep
ad
cell
replic
wild
type
mutant
hbv
respect
confirm
methioninetovalin
mutat
confer
resist
emtricitabin
well
lamivudin
ec
valu
lamivudin
emtricitabin
versu
wild
type
mutant
hbv
im
om
respect
interestingli
introduct
mutat
hbv
polymeras
impart
degre
resist
emtricitabin
lamivudin
seen
upon
introduct
mutat
hiv
polymeras
zoulim
et
al
person
commun
f
zoulim
inserm
franc
use
duck
dhbv
polymeras
assay
report
mutat
confer
resist
lamivudin
show
crossresist
emtricitabin
studi
mutat
made
dhbv
dna
polymeras
correspond
mutat
hbv
inhibitori
activ
lamivudin
emtricitabin
compar
wild
type
mutant
polymeras
use
enzym
express
coupl
transcriptiontransl
rabbit
reticulocyt
lysat
system
lamivudin
emtricitabin
inhibitor
viral
minusstrand
dna
synthesi
icq
valu
ilim
lim
respect
test
mutant
icq
valu
lamivudin
emtricitabin
increas
markedli
illm
cell
cultur
assay
use
lmh
cell
transient
transfect
dhbv
genom
contain
mutat
neither
lamivudin
emtricitabin
show
antivir
activ
cytotox
emtricitabin
evalu
extens
vitro
tabl
cell
line
examin
cell
growth
affect
concentr
emtricitabin
includ
mm
similar
result
obtain
lamivudin
appar
correl
toxic
bone
marrow
progenitor
cell
vitro
bone
marrow
suppress
vivo
human
bone
marrow
progenitor
coloni
form
assay
perform
concentr
emtricitabin
requir
inhibit
format
granulocytemacrophag
gfugm
coloni
cc
im
n
cc
erythroid
coloni
bfue
lim
n
ccq
valu
lamivudin
compar
valu
gfugm
li
valu
bfue
pm
cc
valu
isom
bone
marrow
progenitor
cell
assay
determin
im
gfugm
lim
bfue
interest
f
isom
lamivudin
show
bone
marrow
toxic
isom
emtricitabin
ccq
valu
compar
isom
although
mechan
respons
toxic
side
effect
nucleosid
antivir
agent
multifactori
delay
mitochondri
toxic
believ
major
underli
contributor
previou
studi
ddcinduc
peripher
neuropathi
aztinduc
myopathi
reveal
deplet
mitochondri
dna
content
drugtreat
cell
deplet
could
account
toxic
observ
clinic
effort
evalu
potenti
mitochondri
toxic
human
hepatoblastoma
cell
incub
emtricitabin
concentr
rang
lim
two
week
jim
eight
week
j
jeffrey
person
commun
triangl
pharmaceut
condit
emtricitabin
advers
effect
cell
growth
mitochondri
dna
synthesi
lactic
acid
product
separ
studi
conduct
cell
expos
concentr
emtricitabin
rang
lim
eight
day
effect
mitochondri
morpholog
observ
transmiss
electron
microscopi
vivo
toxicolog
preclin
toxicolog
profil
emtricitabin
extrem
favor
sixmonth
mous
oneyear
monkey
studi
cdi
mice
dose
oral
mgkgday
cynomolgu
monkey
dose
oral
mgkgday
imild
revers
anemia
observ
toxic
anemia
occur
highest
dose
test
plasma
exposur
aucq
mice
approxim
human
exposur
propos
dose
mgday
monkey
plasma
exposur
exceed
human
exposur
accord
vivo
studi
mitochondria
liver
heart
skelet
muscl
examin
transmiss
elect
microscopi
normal
mice
given
oral
dose
emtricitabin
mgkgday
six
month
emtricitabin
effect
reproduct
develop
exposur
approxim
time
human
exposur
reproduct
toxic
studi
consist
fertil
studi
cdi
mice
cd
male
rat
development
toxicolog
studi
conduct
pregnant
mice
pregnant
new
zealand
white
rabbit
genet
toxicolog
studi
consist
ame
assay
mous
lymphoma
assay
assay
use
chines
hamster
ovari
cho
cell
detect
chromosom
aberr
neg
pharmacokinet
metabol
excret
emtricitabin
investig
mice
rat
cynomolgu
monkey
singl
repeat
dose
emtricitabin
rapidli
well
absorb
oral
administr
three
speci
oral
bioavail
rang
peak
plasma
emtricitabin
concentr
occur
hour
post
dose
plasma
concentr
emtricitabin
express
auc
increas
linearli
dose
wide
dose
rang
mgkgday
mice
mgkgday
monkey
plasma
emtricitabin
elimin
halflif
one
four
hour
total
bodi
clearanc
lkghr
rat
la
ghr
monkey
emtricitabin
volum
distribut
vd
lkg
shghtli
larger
total
bodi
water
speci
suggest
distribut
intracellular
extracellular
fluid
space
fraction
proteinbound
emtricitabin
plasma
speci
tissu
distribut
studi
cemtricitabin
rat
monkey
confirm
emtricitabin
wide
distribut
tissu
cradioact
concentr
tissu
gener
declin
parallel
plasma
indic
drug
accumul
virtual
radioact
remain
bodi
hour
postdos
c
concentr
kidney
gut
liver
exceed
plasma
concentr
cn
tissu
plasma
renal
excret
unchang
drug
princip
rout
emtricitabin
eumin
rat
cemtricitabin
dose
recov
urin
iv
dose
oral
dose
approxim
oral
c
dose
recov
urin
mice
monkey
respect
major
dose
recov
fece
oral
dose
like
repres
unabsorb
drug
renal
clearanc
emtricitabin
gener
exceed
glomerular
filtrat
rate
suggest
emtricitabin
excret
renal
tubul
three
speci
metabol
minor
rout
emtricitabin
elimin
mice
monkey
radioact
recov
urin
unchang
drug
princip
metabolit
isomer
account
dose
mice
rat
monkey
metabolit
detect
monkey
urin
metabolit
account
dose
mice
minor
metabolit
dose
detect
detect
speci
clinic
pharmacolog
human
pharmacokinet
phase
iii
studi
pk
disposit
emtricitabin
follow
singleor
multipledos
administr
extens
character
emtricitabin
rapidli
well
absorb
follow
oral
administr
steadyst
plasma
concentr
reach
level
severalfold
mean
vitro
ec
valu
antihiv
activ
figur
hour
postdos
plasma
trough
concentr
follow
mg
qd
dose
exceed
mean
vitro
ecq
antihiv
activ
fourfold
base
extrapol
data
plasma
emtricitabin
concentr
expect
within
rang
ecq
hour
postdos
within
rang
ec
hour
postdos
emtricitabin
disposit
follow
linear
kinet
small
intersubject
variabl
predict
steadyst
concentr
dose
proportion
wide
dose
rang
high
concentr
long
halfliv
emtricitabin
plasma
hour
hour
peripher
blood
mononuclear
cell
pbmc
support
daili
dose
renal
excret
unchang
drug
princip
rout
emtricitabin
elimin
plasma
thu
present
littl
potenti
metabol
drug
interact
plasma
auc
total
bodi
clearanc
appear
correl
creatinin
clearanc
pediatr
dose
mgkg
qd
identifi
evalu
phase
ii
studi
pk
emtricitabin
significantli
affect
coadminist
either
zidovudin
zdv
stavudin
singl
dose
emtricitabin
clinic
signific
pk
effect
increas
auc
c
zdv
respect
due
larg
intersubject
variabihti
small
sampl
size
n
actual
extent
interact
may
less
report
studi
addit
moder
increas
zdv
exposur
observ
would
expect
clinic
signific
clinic
signific
pk
interact
emtricitabin
proteas
inhibitor
indinavir
nonnucleosid
revers
transcriptas
inhibitor
emivirin
observ
follow
singl
oral
administr
emtricitabin
subject
studi
nine
treatmentna
hivinfect
patient
enrol
trial
simultan
administr
ftc
ddl
efavirenz
significantli
affect
pk
drug
emtricitabin
primarili
elimin
unchang
drug
urin
studi
focus
potenti
interact
emtricitabin
famciclovir
site
urinari
excret
conduct
famciclovir
chosen
typic
drug
evalu
activ
form
plasma
penciclovir
primarili
elimin
urin
interact
seen
random
control
studi
confirm
doserespons
result
potent
antivir
activ
occur
emtricitabin
mg
qd
dose
group
figur
median
chang
baselin
day
logjq
mg
qd
emtricitabin
dose
respect
logjq
mg
bid
lamivudin
dose
result
statist
analys
rna
aaucmb
chang
baselin
day
last
day
studi
treatment
maximum
chang
baselin
consist
distinguish
mg
qd
lower
emtricitabin
dose
addit
greater
activ
emtricitabin
mg
qd
base
chang
baselin
rna
also
greater
proport
patient
achiev
limit
assay
detect
copiesml
two
log
decreas
baselin
ftc
mg
qd
dose
figur
doserespons
relationship
evalu
correl
hivrna
aaucmb
emtricitabin
daili
dose
use
pharmacolog
e
model
e
e
dose
dose
pharmacolog
doserespons
curv
show
effect
emtricitabin
rna
suppress
reach
maxim
effect
dose
mg
per
day
littl
addit
effect
rna
suppress
observ
increas
dose
mg
mg
per
day
overal
patient
complet
studi
reason
earli
termin
studi
similar
treatment
group
thirteen
patient
ftc
group
discontinu
studi
earli
due
advers
event
one
patient
die
due
heroin
overdos
group
week
therapi
proport
patient
confirm
virolog
loss
respons
ftc
arm
arm
find
support
conclus
equival
safeti
virolog
efficaci
mg
daili
ftc
compar
mg
administ
twice
daili
studi
random
doubleblind
equival
studi
ftc
versu
combin
stavudin
either
nevirapin
patient
rna
copiesml
efavirenz
patient
rna
copiesml
antiretroviralna
patient
patient
treat
receiv
plu
stavudin
nevirapin
receiv
plu
stavudin
efavirenz
seventyfour
percent
patient
complet
week
therapi
treatment
group
compar
regard
race
gender
age
baselin
characterist
median
age
entri
year
rang
black
african
femal
median
screen
cell
count
cellsmm
rang
median
plasma
rna
log
copiesml
major
patient
treatment
arm
achiev
maintain
plasma
rna
copiesml
week
receiv
ftc
receiv
ftc
patient
plasma
rna
copiesml
week
thirtythre
ftctreat
patient
patient
confirm
virolog
failur
studi
interestingli
ftctreat
virolog
failur
genotyp
chang
associ
medic
use
tripl
therapi
regimen
compar
three
patient
seven
ftcand
patient
respect
mutat
time
failur
immunolog
benefit
observ
week
compar
treatment
arm
mean
increas
baselin
absolut
cell
count
approxim
cellsmm
increas
eleven
percent
patient
treatment
arm
discontinu
blind
studi
medic
due
advers
event
studi
major
discontinu
associ
hepatotox
attribut
use
nevirapin
tripl
therapi
regimen
result
confirm
patient
treatment
arm
studi
deriv
signific
virolog
immunolog
benefit
trial
result
trial
compar
favor
random
wellcontrol
intern
clinic
trial
use
standardofcar
tripl
therapi
regimen
support
conclus
equival
efficaci
safeti
ftc
pilot
doseselect
studi
design
examin
pharmacokinet
activ
emtricitabin
treatment
chronic
hbv
infect
five
oncedaili
dose
emtricitabin
mg
mg
mg
mg
mg
evalu
sequenti
eight
week
cohort
consist
least
eight
patient
chronic
hbv
infect
patient
posit
hbsag
hbv
dna
naiv
nucleosid
analog
therapi
pharmacokinet
analysi
show
emtricitabin
well
absorb
oral
administr
plasma
concentr
reach
level
ec
dose
oncedaili
administr
elimin
halflif
emtricitabin
plasma
rang
six
hour
steadyst
plasma
concentr
increas
nearli
dose
proport
mg
mg
dose
rang
suppress
hbv
dna
depend
baselin
viral
load
assay
sensit
complet
dose
day
hbv
dna
suppress
reach
undetect
level
assay
digen
hybrid
captur
assay
lower
limit
detect
copiesml
low
moder
baselin
viral
load
show
dose
effect
high
baselin
viral
load
use
chiron
hbv
monitor
assay
lower
limit
detect
copiesml
hbv
suppress
greater
log
observ
absolut
interpret
dose
respons
complic
studi
differ
viral
load
baselin
cohort
sequenti
enrol
consist
report
hiv
trial
emtricitabin
well
toler
seriou
advers
event
patient
intoler
drug
observ
advers
event
grade
iiiii
sever
headach
occur
patient
overal
doubleblind
random
trial
evalu
three
dose
emtricitabin
mg
mg
mg
qd
total
patient
enrol
mg
dose
cohort
mg
dose
cohort
mean
age
patient
year
male
asian
ethnic
import
demograph
differ
among
dose
cohort
median
baselin
viral
load
logjq
cml
mg
qd
mg
qd
mg
qd
cohort
respect
initi
treatment
period
set
week
extend
blind
fashion
week
emtricitabin
produc
potent
inhibit
hbv
dna
dosedepend
manner
median
chang
baselin
hbv
dna
mg
qd
dose
group
log
respect
similar
dose
respons
seen
suppress
hbv
dna
analyz
aaucmb
howev
differ
dose
pronounc
hbv
suppress
view
percentag
patient
viral
load
fall
limit
detect
lod
percent
patient
hbv
dna
lod
mg
qd
dose
cohort
mg
qd
dose
cohort
mg
qd
dose
cohort
base
data
mg
qd
dose
select
evalu
pivot
therapeut
trial
doubleblind
random
placebocontrol
pivot
studi
design
prove
safeti
efficaci
emtricitabin
mg
qd
dose
treatment
chronic
hbv
infect
appar
emtricitabin
repres
one
potent
antihiv
agent
identifi
date
produc
almost
two
log
drop
viral
load
monotherapi
mg
qd
dose
addit
clinic
profil
emtricitabin
demonstr
follow
key
featur
plasma
halflif
approxim
eight
hour
linear
kinet
intracellular
emtricitabin
halflif
greater
hour
support
daili
dose
signific
drug
drug
interact
would
limit
use
emtricitabin
combin
therapi
compar
safeti
efficaci
lamivudin
low
incid
mutat
extrem
import
observ
suggest
emtricitabin
could
increas
durabl
oxathiolan
nucleosid
analogcontain
drug
regimen
although
hbv
clinic
develop
program
enter
pivot
phase
alreadi
data
suggest
mg
qd
dose
select
hiv
develop
lower
incid
mutat
histor
report
lamivudin
hiv
observ
hold
possibl
durabl
therapi
treatment
chronic
hbv
infect
also
suggest
emtricitabin
extrem
import
drug
treatment
patient
coinfect
hiv
hbv
